open access
Markers of proliferation and invasiveness in somatotropinomas


- Department of Endocrinology, Faculty of Medicine Jagiellonian University, Medical College, Mikolaja Kopernika 17, 31-501 Krakow, Poland
- Katedra i Klinika Endokrynologii, Uniwersytet Jagielloński, Collegium Medicum, Mikołaja Kopernika 17, 31-501 Kraków, Poland
- Chair of Gastroenterology, Hepatology and Infectious Diseases, Faculty of Medicine Jagiellonian University, Medical College, ul. Sniadeckich 5, 31-531 Krakow, Poland
- Katedra Gastroenterologii, Hepatologii i Chorób Zakaźnych, Uniwersytet Jagielloński, Collegium Medicum, ul. Śniadeckich 5, 31-531 Kraków, Poland
- Chair of Patomorphology, Faculty of Medicine Jagiellonian University, Medical College, Grzegórzecka 16, 31-531 Kraków, Poland
- Katedra Patomorfologii, Uniwersytet Jagielloński, Collegium Medicum, ul. Grzegórzecka 16, 31-531 Kraków, Poland
open access
Abstract
Abstract
Keywords
pituitary adenoma, markers of proliferation, Ki-67, TOPO 2A, AIP, VEGF


Title
Markers of proliferation and invasiveness in somatotropinomas
Journal
Issue
Article type
Original paper
Pages
182-189
Published online
2018-01-12
Page views
2920
Article views/downloads
1268
DOI
Pubmed
Bibliographic record
Endokrynol Pol 2018;69(2):182-189.
Keywords
pituitary adenoma
markers of proliferation
Ki-67
TOPO 2A
AIP
VEGF
Authors
Agata Baldys-Waligorska
Iga Wierzbicka
Grzegorz Sokolowski
Dariusz Adamek
Filip Golkowski


- Dworakowska D, Grossman AB. The pathophysiology of pituitary adenomas. Best Pract Res Clin Endocrinol Metab. 2009; 23(5): 525–541.
- Bałdys-Waligórska A, Krzentowska-Korek A, Gołkowski F, et al. The predictive value of the IGF-1 level in acromegaly patients treated by surgery and a somatostatin analogue. Endokrynol Pol. 2011; 62(5): 401–408.
- Meij BP, Lopes MBS, Ellegala DB, et al. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg. 2002; 96(2): 195–208.
- Trouillas J, Roy P, Sturm N, et al. members of HYPOPRONOS. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol. 2013; 126(1): 123–135.
- DeLellis RA, Lloyd RV, Heitz PU. Pathology and Genetics of Tumors of Endocrine Organs. In: World Health Organisation Classification of Tumors. IARC Press, Lyon 2004: 9–47.
- Wolfsberger S, Knosp E. Comments on the WHO 2004 classification of pituitary tumors. Acta Neuropathol. 2006; 111(1): 66–67.
- Zada G, Woodmansee WW, Ramkissoon S, et al. Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg. 2011; 114(2): 336–344.
- Gruppetta M, Formosa R, Falzon S, et al. Expression of cell cycle regulators and biomarkers of proliferation and regrowth in human pituitary adenomas. Pituitary. 2017; 20(3): 358–371.
- Al-Shraim M, Asa SL. The 2004 World Health Organization classification of pituitary tumors: what is new? Acta Neuropathol. 2006; 111(1): 1–7.
- Clarke DJ, Vas AC, Andrews CA, et al. Topoisomerase II checkpoints: universal mechanisms that regulate mitosis. Cell Cycle. 2006; 5(17): 1925–1928.
- Vidal S, Kovacs K, Horvath E, et al. Topoisomerase IIalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior. Mod Pathol. 2002; 15(11): 1205–1212.
- Cao Yi, Ke R, Wang S, et al. DNA topoisomerase IIα and Ki67 are prognostic factors in patients with hepatocellular carcinoma. Oncol Lett. 2017; 13(6): 4109–4116.
- Trofimiuk-Müldner M, Bałdys-Waligórska A, Sokołowski G, et al. Topoisomerase IIα as a prognostic factor in pituitary tumors. Pol Arch Med Wewn. 2014; 124(10): 500–508.
- Wolfsberger S, Wunderer J, Zachenhofer I, et al. Expression of cell proliferation markers in pituitary adenomas--correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha. Acta Neurochir (Wien). 2004; 146(8): 831–839.
- Hernández-Ramírez LC, Martucci F, Morgan RML, et al. Rapid Proteasomal Degradation of Mutant Proteins Is the Primary Mechanism Leading to Tumorigenesis in Patients With Missense AIP Mutations. J Clin Endocrinol Metab. 2016; 101(8): 3144–3154.
- Sav A, Rotondo F, Syro LV, et al. Biomarkers of pituitary neoplasms. Anticancer Res. 2012; 32(11): 4639–4654.
- Schöfl C, Honegger J, Droste M, et al. Frequency of AIP gene mutations in young patients with acromegaly: a registry-based study. J Clin Endocrinol Metab. 2014; 99(12): E2789–E2793.
- Kasuki L, Vieira Neto L, Wildemberg LE, et al. AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression. Endocr Relat Cancer. 2012; 19(3): L25–L29.
- Siveen KS, Prabhu K, Krishnankutty R, et al. Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges. Curr Vasc Pharmacol. 2017; 15(4): 339–351.
- McCabe CJ, Boelaert K, Tannahill LA, et al. Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab. 2002; 87(9): 4238–4244.
- Knosp E, Steiner E, Kitz K, et al. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery. 1993; 33(4): 610–7; discussion 617.
- Zada G, Lin N, Laws ER. Patterns of extrasellar extension in growth hormone-secreting and nonfunctional pituitary macroadenomas. Neurosurg Focus. 2010; 29(4): E4.
- Wierzbicka-Tutka I, Sokołowski G, Bałdys-Waligórska A, et al. PTTG and Ki-67 expression in pituitary adenomas. Przegl Lek. 2016; 73(2): 53–58.
- Landeiro JA, Fonseca EO, Monnerat AL, et al. Nonfunctioning giant pituitary adenomas: Invasiveness and recurrence. Surg Neurol Int. 2015; 6: 179.
- Sarkar S, Chacko AG, Chacko G. An analysis of granulation patterns, MIB-1 proliferation indices and p53 expression in 101 patients with acromegaly. Acta Neurochir (Wien). 2014; 156(12): 2221–30; discussion 2230.
- Chacko G, Chacko AG, Lombardero M, et al. Clinicopathologic correlates of giant pituitary adenomas. J Clin Neurosci. 2009; 16(5): 660–665.
- Jaffrain-Rea ML, Angelini M, Gargano D, et al. Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocr Relat Cancer. 2009; 16(3): 1029–1043.
- Lloyd RV, Scheithauer BW, Kuroki T, et al. Vascular Endothelial Growth Factor (VEGF) Expression in Human Pituitary Adenomas and Carcinomas. Endocr Pathol. 1999; 10(3): 229–235.
- Sánchez-Ortiga R, Sánchez-Tejada L, Moreno-Perez O, et al. Over-expression of vascular endothelial growth factor in pituitary adenomas is associated with extrasellar growth and recurrence. Pituitary. 2013; 16(3): 370–377.
- Wang Y, Li J, Tohti M, et al. The expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapy. J Exp Clin Cancer Res. 2014; 33: 56.
- Kurosaki M, Saegert W, Abe T, et al. Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: special reference to the octreotide treatment. Neurol Res. 2008; 30(5): 518–522.
- Alimohamadi M, Ownagh V, Mahouzi L, et al. The impact of immunohistochemical markers of Ki-67 and p53 on the long-term outcome of growth hormone-secreting pituitary adenomas: A cohort study. Asian J Neurosurg. 2014; 9(3): 130–136.
- Jaffrain-Rea ML, Rotondi S, Turchi A, et al. Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations. Endocr Relat Cancer. 2013; 20(5): 753–766.
- Kasuki Jomori de Pinho L, Vieira Neto L, Armondi Wildemberg LE, et al. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53. Neuroendocrinology. 2011; 94(1): 39–48.
- Yilmaz M, Vural E, Koc K, et al. Cavernous sinus invasion and effect of immunohistochemical features on remission in growth hormone secreting pituitary adenomas. Turk Neurosurg. 2015; 25(3): 380–388.
- Yarman S, Kurtulmus N, Canbolat A, et al. Expression of Ki-67, p53 and vascular endothelial growth factor (VEGF) concomitantly in growth hormone-secreting pituitary adenomas; which one has a role in tumor behavior ? Neuro Endocrinol Lett. 2010; 31(6): 823–828.
- Sen A, Das C, Mukhopadhyay M, et al. Cytohistological correlation in pituitary tumor and immunological assessment with the help of Ki-67. J Postgrad Med. 2017; 63(2): 96–99.
- Dénes J, Kasuki L, Trivellin G, et al. Regulation of aryl hydrocarbon receptor interacting protein (AIP) protein expression by MiR-34a in sporadic somatotropinomas. PLoS One. 2015; 10(2): e0117107.
- Magagna-Poveda A, Leske H, Schmid C, et al. Expression of somatostatin receptors, angiogenesis and proliferation markers in pituitary adenomas: an immunohistochemical study with diagnostic and therapeutic implications. Swiss Med Wkly. 2013; 143: w13895.
- Ritvonen E, Pitkänen E, Karppinen A, et al. Impact of AIP and inhibitory G protein alpha 2 proteins on clinical features of sporadic GH-secreting pituitary adenomas. Eur J Endocrinol. 2017; 176(2): 243–252.
- Chahal HS, Trivellin G, Leontiou CA, et al. Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. J Clin Endocrinol Metab. 2012; 97(8): E1411–E1420.
- Zawada NB, Kunert-Radek J, Pawlikowski M, et al. An evaluation of the effects of somatostatin analogue therapy in non-functioning pituitary adenomas in comparison to acromegaly. Endokrynol Pol. 2016; 67(3): 292–298.